Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gong, H.
Right arrow Articles by Lin, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gong, H., Jr
Right arrow Articles by Lin, A. E.
(Chest. 1996;110:1229-1235.)
© 1996 American College of Chest Physicians

Effect of Inhaled Salmeterol on Sulfur Dioxide-Induced Bronchoconstriction in Asthmatic Subjects

Henry Gong Jr MD, FCCP1; William S. Linn MA1; Deborah A. Shamoo MS1; Karen R. Anderson BS1; Cheryl A. Nugent BS1; Kenneth W. Clark MS1; and Andy E. Lin BS1

1 From the Environmental Health Service, Rancho Los Amigos Medical Center, Downey, Calif, and School of Medicine, University of Southern California, Los Angeles

This study tested the capability of a single 42-µg dose of inhaled salmeterol xinafoate, a long-acting β2-agonist, to protect against bronchoconstrictive effects of exposure to 0.75 ppm sulfur dioxide (SO2) during exercise, for up to 24 h. Ten SO2-responsive adult volunteers with stable asthma were studied under 4 conditions of drug pretreatment/exposure, administered in random order, doubleblind: salmeterol/SO2, placebo/SO2, salmeterol/clean air, and placebo/clean air. Each subject underwent 10-min exposure/exercise challenges in a chamber 1, 12, 18, and 24 h after pretreatment. Exercise ventilation rates averaged 29 L/min. Response was measured as the decrement in FEV1 between preexposure and postexposure (lowest value within 30 min). After salmeterol, mean decrement post-SO2 was 7% at 1 h and 12% at 12 h. At 18 and 24 h after salmeterol, and at all times after placebo, mean decrements were 25 to 30%. After 18 and 24 h, salmeterol still improved baseline FEV1 relative to placebo, although improvement was not statistically significant at 24 h. Acute symptom increases accompanied FEV1 decrements.

Conclusion: In our asthmatic subjects, pretreatment with salmeterol imparted clinically and statistically significant (p<0.01) protection against bronchoconstriction induced by SO2/exercise for at least 12 h, and maintained an improvement in lung function for as much as 18 h.

Key Words: asthma • β-agonists • lung function • salmeterol xinafoate • sulfur dioxide

Submitted on February 9, 1996
Accepted on May 24, 2007




This article has been cited by other articles:


Home page
 ChestHome page
H. Gong Jr., W. S. Linn, S. L. Terrell, K. R. Anderson, and K. W. Clark
Anti-inflammatory and Lung Function Effects of Montelukast in Asthmatic Volunteers Exposed to Sulfur Dioxide
Chest, February 1, 2001; 119(2): 402 - 408.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.